Cell & Gene Therapy Logistics
This carefully curated collection features companies providing the essential infrastructure that makes advanced cell and gene therapies possible. Selected by expert analysts, these stocks represent the "picks and shovels" of the biotech revolution—giving you exposure to regenerative medicine's growth without the direct risks of clinical trials.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
About This Group of Stocks
Our Expert Thinking
We're focused on the companies behind the scenes making cell and gene therapy possible. Instead of betting on which treatments will succeed, we've selected the firms providing crucial infrastructure—from cryogenic storage to manufacturing components—that all therapies need regardless of clinical outcomes.
What You Need to Know
These stocks offer a different risk profile than traditional biotech investments. While they still operate in a fast-evolving sector, their services remain essential regardless of which specific therapies ultimately succeed, providing a more stable approach to capturing growth in advanced medicine.
Why These Stocks
Each company was selected because they provide irreplaceable services in the cell and gene therapy supply chain. As more advanced treatments receive regulatory approval, these firms face increasing demand for their specialized logistics, manufacturing capabilities, and quality control systems.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+350.01%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 350.01% over the next year.
Stocks Rated Buy by Analysts
13 of 15 assets in this group are rated Buy by professional analysts.
Why You'll Want to Watch These Stocks
The Cold Chain Craze
Cell and gene therapies need ultra-cold storage and transport to work. As more of these treatments get approved, the companies keeping them frozen become critical—an opportunity most investors are missing.
The Invisible Winners
While headline-grabbing biotech firms often face binary outcomes based on clinical trials, these behind-the-scenes companies earn revenue regardless of which therapies ultimately succeed—potentially offering smoother growth.
Riding The Approval Wave
With cell and gene therapy approvals accelerating, demand for specialized manufacturing and logistics is surging. These companies are positioned to benefit from this momentum as the field transforms from experimental to mainstream.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Consumer Caution: Value Prevails
A sharp drop in consumer sentiment, driven by persistent inflation fears, signals a potential shift in household spending. This theme focuses on companies poised to benefit as consumers prioritize essential goods and seek value.
Refining a New Opportunity: Venezuelan Crude Returns
Following a renewed U.S. license, Chevron has resumed oil shipments from Venezuela, creating a new supply of heavy crude for the market. This development presents a potential investment opportunity in U.S. refiners and logistics firms positioned to benefit from this strategic shift.
Consumer Strength: The Retail Rebound
A surprising surge in U.S. retail sales, driven by strong automotive and home furnishing purchases, signals continued consumer strength despite economic headwinds. This theme focuses on retailers and manufacturers in these key discretionary sectors that are benefiting from the robust consumer demand.
Frequently Asked Questions
Everything you need to know about the product and billing.